Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00442832 | TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection | PHASE2 | COMPLETED | 203 | — | — | Dec 1, 2006 | May 1, 2007 | Jan 20, 2021 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| TD-1792 | EXPERIMENTAL | - |
| Vancomycin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TD-1792 | DRUG | TD-1792 2 mg/kg/day IV |
| Vancomycin | DRUG | Vancomycin 1 Gm IV q 12 hrs |
Inclusion Criteria: * major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections * requires at least 7 days of intravenous antibiotic treatment Exclusion Criteria: * more than 24 hours of antibiotic therapy * moderate or sever...